1. Kalivas, P. W. & O’Brien, C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 33, 166–180 (2008).

2. Koob, G. F. & Volkow, N. D. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3, 760–773 (2016).

3. O’Brien, C. P., Childress, A. R., Ehrman, R. & Robbins, S. J. Conditioning factors in drug abuse: can they explain compulsion? J. Psychopharmacol. 12, 15–22 (1998).

4. Heard, K., Palmer, R. & Zahniser, N. R. Mechanisms of acute cocaine toxicity. Open Pharmacol. J. 2, 70–78 (2008).

5. Zimmerman, J. L. Cocaine intoxication.Crit. Care Clin. 28, 517–526 (2012).

6. Brimijoin, S. Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol. Disord. Drug Targets 10, 880–891 (2011).

7. Lockridge, O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol. Ther. 148, 34–46 (2015).

8. Schindler, C. W. & Goldberg, S. R. Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity. Future Med. Chem. 4, 163–175 (2012).

9. Murthy, V. et al. Reward and toxicity of cocaine metabolites generated by cocaine hydrolase. Cell. Mol. Neurobiol. 35, 819–826 (2015).

10. Sun, H. et al. Predicted Michaelis–Menten complexes of cocaine-butyrylcholinesterase. Engineering effective butyrylcholinesterase mutants for cocaine detoxication. J. Biol. Chem. 276, 9330–9336 (2001).

11. Sun, H., Pang, Y. P., Lockridge, O. & Brimijoin, S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol. Pharmacol. 62, 220–224 (2002).

12. Xue, L. et al. Catalytic activities of a cocaine hydrolase engineered from human butyrylcholinesterase against (+)- and (−)-cocaine. Chem. Biol. Interact. 203, 57–62 (2013).

13. Zheng, F. et al. Most efficient cocaine hydrolase designed by virtual screening of transition states. J. Am. Chem. Soc. 130, 12148–12155 (2008).

14. Zheng, F. et al. A highly efficient cocaine-detoxifying enzyme obtained by computational design. Nat. Commun. 5, 3457 (2014).

15. Connors, N. J. & Hoffman, R. S. Experimental treatments for cocaine toxicity: a difficult transition to the bedside. J. Pharmacol. Exp. Ther. 347, 251–257 (2013).

16. Cohen-Barak, O. et al. Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects. J. Clin. Pharmacol. 55, 573–583 (2015).

17. Gilgun-Sherki, Y. et al. Placebo-controlled evaluation of a bioengineered, cocaine-metabolizing fusion protein, TV-1380 (AlbuBChE), in the treatment of cocaine dependence.Drug Alcohol Depend. 166, 13–20 (2016).

18. Kotterman, M. A., Chalberg, T. W. & Schaffer, D. V. Viral vectors for gene therapy: translational and clinical outlook. Annu. Rev. Biomed. Eng. 17, 63–89 (2015).

19. Naldini, L. Gene therapy returns to centre stage. Nature 526, 351–360 (2015).

20. Yue, J., Gou, X., Li, Y., Wicksteed, B. & Wu, X. Engineered epidermal progenitor cells can correct diet-induced obesity and diabetes. Cell Stem Cell. 21, 256–263 (2017).

21. Liu, H. et al. Regulation of focal adhesion dynamics and cell motility by the EB2 and Hax1 protein complex. J. Biol. Chem. 290, 30771–30782 (2015).

22. Yue, J. et al. In vivo epidermal migration requires focal adhesion targeting of ACF7. Nat. Commun. 7, 11692 (2016).

23. Rasmussen, C., Thomas-Virnig, C. & Allen-Hoffmann, B. L. Classical human epidermal keratinocyte cell culture. Methods Mol. Biol. 945, 161–175 (2013).

24. Rheinwald, J. G. & Green, H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6, 331–343 (1975).

25. Rheinwald, J. G. & Green, H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 265, 421–424 (1977).

26. Blanpain, C. & Fuchs, E. Epidermal stem cells of the skin. Annu. Rev. Cell. Dev. Biol. 22, 339–373 (2006).

27. Watt, F. M. Mammalian skin cell biology: at the interface between laboratory and clinic. Science 346, 937–940 (2014).

28. Carsin, H. et al. Cultured epithelial autografts in extensive burn coverage of severely traumatized patients: a five year single-center experience with 30 patients. Burns 26, 379–387 (2000).

29. Coleman, J. J. 3rd & Siwy, B. K. Cultured epidermal autografts: a life-saving and skin-saving technique in children. J. Pediatr. Surg. 27, 1029–1032 (1992).

30. Haniffa, M., Gunawan, M. & Jardine, L. Human skin dendritic cells in health and disease. J. Dermatol. Sci. 77, 85–92 (2015).

31. Christensen, R., Jensen, U. B. & Jensen, T. G. Skin genetically engineered as a bioreactor or a ‘metabolic sink’. Cells Tissues Organs 172, 96–104 (2002).

32. Del Rio, M., Gache, Y., Jorcano, J. L., Meneguzzi, G. & Larcher, F. Current approaches and perspectives in human keratinocyte-based gene therapies. Gene Ther. 11, S57–S63 (2004).

33. Fakharzadeh, S. S., Zhang, Y., Sarkar, R. & Kazazian, H. H. Jr. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 95, 2799–2805 (2000).

34. Fenjves, E. S., Gordon, D. A., Pershing, L. K., Williams, D. L. & Taichman, L. B. Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes: implications for epidermal function and gene therapy. Proc. Natl Acad. Sci. USA 86, 8803–8807 (1989).

35. Gerrard, A. J., Hudson, D. L., Brownlee, G. G. & Watt, F. M. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat. Genet. 3, 180–183 (1993).

36. Morgan, J. R., Barrandon, Y., Green, H. & Mulligan, R. C. Expression of an exogenous growth hormone gene by transplantable human epidermal cells. Science 237, 1476–1479 (1987).

37. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.Cell 154, 1380–1389 (2013).

38. Chen, X. et al. Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. Biochem. J. 466, 243–251 (2015).

39. Schober, M. & Fuchs, E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc. Natl Acad. Sci. USA 108, 10544–10549 (2011).

40. Sebastiano, V. et al. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci. Transl. Med. 6, 264ra163 (2014).

41. Koob, G. F. & Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology 35, 217–238 (2010).

42. Wong, J. M. et al. Benzoyl chloride derivatization with liquid chromatography–mass spectrometry for targeted metabolomics of neurochemicals in biological samples.J. Chromatogr. A 1446, 78–90 (2016).

43. Cunningham, C. L., Gremel, C. M. & Groblewski, P. A.Drug-induced conditioned place preference and aversion in mice.Nat. Protoc. 1, 1662–1670 (2006).

44. Yan, Y., Kong, H., Wu, E. J., Newman, A. H., & Xu, M. Dopamine D3 receptors regulate reconsolidation of cocaine memory. Neuroscience 241, 32–40 (2013).

45. Still, J. M. Jr, Orlet, H. K. & Law, E. J. Use of cultured epidermal autografts in the treatment of large burns. Burns 20, 539–541 (1994).

46. Guerra, L. et al. Treatment of ‘stable’ vitiligo by timedsurgery and transplantation of cultured epidermal autografts. Arch. Dermatol. 136, 1380–1389 (2000).

47. Shinkuma, S. et al. Long-term follow-up of cultured epidermal autograft in a patient with recessive dystrophic epidermolysis bullosa. Acta Derm. Venereol. 94, 98–99 (2014).

48. Collins, G. T. et al. Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J. Pharmacol. Exp. Ther. 331, 445–455 (2009).

49. Sandoval, D. A. & D’Alessio, D. A. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95, 513–548 (2015).

50. Egecioglu, E. et al. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38, 1259–1270 (2013).

51. Shirazi, R. H., Dickson, S. L. & Skibicka, K. P. Gut peptide GLP-1 and its analogue, exendin-4, decrease alcohol intake and reward. PLoS ONE 8, e61965 (2013).

52. Skibicka, K. P. The central GLP-1: implications for food and drug reward.Front. Neurosci. 7, 181 (2013).

53. Sorensen, G., Caine, S. B. & Thomsen, M. Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice. Alcohol. Clin. Exp. Res. 40, 2247–2252 (2016).

54. Sorensen, G. et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.Physiol. Behav. 149, 262–268 (2015).

55. Vallof, D. et al. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict. Biol. 21, 422–437 (2016).

56. Collins, M. & Thrasher, A. Gene therapy: progress and predictions.Proc. Biol Sci. 282, 20143003 (2015).

57. Yue, J. et al.In vivo epidermal migration requires focal adhesion targeting of ACF7. Nat. Commun. 7, 11692 (2016).

58. Prunieras, M., Regnier, M. & Woodley, D. Methods for cultivation of keratinocytes with an air–liquid interface. J. Invest. Dermatol. 81, 28s–33s (1983).

59. Guasch, G. et al. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12, 313–327 (2007).

60. Wu, X., Suetsugu, S., Cooper, L. A., Takenawa, T. & Guan, J. L. Focal adhesion kinase regulation of N-WASP subcellular localization and function. J. Biol. Chem. 279, 9565–9576 (2004).